Key terms

About ANIP

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ANIP news

May 14 4:23pm ET ANI Pharmaceuticals Financial Health Overview Released May 13 7:10am ET Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX) May 13 6:20am ET Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Fate Therapeutics (FATE) and Instil Bio (TIL) May 13 6:02am ET ANI Pharmaceuticals price target raised to $87 from $83 at H.C. Wainwright May 10 6:59am ET ANI Pharmaceuticals sees 2024 adjusted EPS $4.26-$4.67, consensus $4.48 May 10 6:55am ET ANI Pharmaceuticals reports Q1 adjusted EPS $1.21, consensus $1.00 Apr 17 8:12am ET ANI Pharmaceuticals Financial Report: Key Insights Revealed Mar 27 6:51am ET ANI Pharmaceuticals announces launch of Levofloxacin Oral Solution Mar 15 7:32am ET ANI Pharmaceuticals initiated with an Overweight at Capital One Mar 12 7:22am ET ANI Pharmaceuticals: Current Performance Insights Revealed Mar 05 6:24am ET ANI Pharmaceuticals price target raised to $77 from $70 at Guggenheim Mar 04 6:15am ET ANI Pharmaceuticals price target raised to $83 from $73 at H.C. Wainwright Mar 03 10:33am ET Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), ANI Pharmaceuticals (ANIP) and Merck & Company (MRK) Mar 01 7:56am ET ANI Pharmaceuticals price target raised to $80 from $72 at Truist Feb 29 6:52am ET ANI Pharmaceuticals sees FY24 adjusted EPS $4.26-$4.67, consensus $4.33 Feb 29 6:51am ET ANI Pharmaceuticals reports Q4 adjusted EPS $1.00, consensus 85c Feb 27 7:51am ET Analysts Are Bullish on Top Healthcare Stocks: ANI Pharmaceuticals (ANIP), Boston Scientific (BSX) Feb 24 10:13am ET ANI Pharmaceuticals Sells Ontario Facility for $14.2M USD

No recent press releases are available for ANIP

ANIP Financials

1-year income & revenue

Key terms

ANIP Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ANIP Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms